Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Decoding Carboprost Tromethamine: A Comprehensive Study of its R&D Trends and Mechanism on Drug Target
Drug Insights
4 min read
Decoding Carboprost Tromethamine: A Comprehensive Study of its R&D Trends and Mechanism on Drug Target
30 September 2023
This article summarized the latest R&D progress of Carboprost Tromethamine, the Mechanism of Action for Carboprost Tromethamine, and the drug target R&D trends for Carboprost Tromethamine.
Read →
Advances in Clinical Research on PPAR Agonists
Advances in Clinical Research on PPAR Agonists
30 September 2023
PPAR, or peroxisome proliferator-activated receptor, is a group of nuclear receptor proteins found in the human body.
Read →
Deep Scientific Insights on Carbidopa/Levodopa's R&D Progress, Mechanism of Action, and Drug Target
Drug Insights
4 min read
Deep Scientific Insights on Carbidopa/Levodopa's R&D Progress, Mechanism of Action, and Drug Target
30 September 2023
This article summarized the latest R&D progress of Carbidopa/Levodopa, the Mechanism of Action for Carbidopa/Levodopa, and the drug target R&D trends for Carbidopa/Levodopa.
Read →
Lutathera®, a Novartis radioligand therapy, significantly improved progression-free survival rates in early advanced GEP-NETs
Latest Hotspot
3 min read
Lutathera®, a Novartis radioligand therapy, significantly improved progression-free survival rates in early advanced GEP-NETs
30 September 2023
Lutathera®, a radioligand therapy by Novartis, showed significant progression-free survival rates in initial stage advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Read →
An In-depth Analysis of Brentuximab Vedotin's R&D Progress and Mechanism of Action on Drug Target
Drug Insights
4 min read
An In-depth Analysis of Brentuximab Vedotin's R&D Progress and Mechanism of Action on Drug Target
30 September 2023
This article summarized the latest R&D progress of Brentuximab Vedotin, the Mechanism of Action for Brentuximab Vedotin, and the drug target R&D trends for Brentuximab Vedotin.
Read →
Analysis on the Research Progress of Protease inhibitors
Analysis on the Research Progress of Protease inhibitors
30 September 2023
Proteases are enzymes that play a crucial role in the human body by breaking down proteins into smaller peptides or amino acids.
Read →
Arformoterol Tartrate: Detailed Review of its Transformative R&D Success
Drug Insights
4 min read
Arformoterol Tartrate: Detailed Review of its Transformative R&D Success
30 September 2023
Arformoterol Tartrate is a small molecule drug that targets the β2-adrenergic receptor. It is primarily used in the treatment of various respiratory diseases.
Read →
Henlius' Innovative Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Receives Approval for Use in Treating ESCC
Latest Hotspot
4 min read
Henlius' Innovative Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Receives Approval for Use in Treating ESCC
30 September 2023
Shanghai Henlius Biotech, Inc. has made a public announcement that the NMPA has given approval to the NDA for an innovative fresh indication of HANSIZHUANG (serplulimab injection).
Read →
Doxepin Hydrochloride Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs
Drug Insights
4 min read
Doxepin Hydrochloride Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs
30 September 2023
This article summarized the latest R&D progress of Doxepin Hydrochloride, the Mechanism of Action for Doxepin Hydrochloride, and the drug target R&D trends for Doxepin Hydrochloride.
Read →
New Epigenetic Drug Targets: PRMT5 Inhibitors
New Epigenetic Drug Targets: PRMT5 Inhibitors
30 September 2023
PRMT5 expression is associated with a poor prognosis in tumor progression and metastasis.
Read →
Unleashing the Power of Torsemide: A Comprehensive Review on R&D Breakthroughs
Drug Insights
4 min read
Unleashing the Power of Torsemide: A Comprehensive Review on R&D Breakthroughs
30 September 2023
This article summarized the latest R&D progress of Torsemide, the Mechanism of Action for Torsemide, and the drug target R&D trends for Torsemide.
Read →
SELLAS announces promising initial results from the SLS009 Phase 1 lymphoma group study, advancing to Phase 2 clinical trial
Latest Hotspot
3 min read
SELLAS announces promising initial results from the SLS009 Phase 1 lymphoma group study, advancing to Phase 2 clinical trial
30 September 2023
SELLAS reveals uplifting preliminary findings in Lymphoma group from SLS009 Phase 1 Increasing-Dose Study, promoting progression to Phase 2 Clinical Experiment.
Read →